Loading...

GENE VECTOR PLATFORMS FOR SMARTER CANCER IMMUNOTHERAPIES

DEVELOPS GENE-ENGINEERING TECHNOLOGIES FOR ADVANCED THERAPIES MEDICINAL PRODUCTS

DISCOVER OUR SCIENCE
Scroll Down

Our Mission

Our MISSION is to develop new gene expression systems that improve the efficacy and safety of advanced cancer immunotherapies.

LentiStem Biotech is a highly innovative biotechnology company dedicated to the development of lentiviral vectors and genetic modification strategies applied to next-generation gene and cellular therapy.

Safety

Developing vectors that minimize off-target effects and improve patient safety profiles.

Efficiency

Improving efficiency of cell modifications.

Challenges in CAR-T Cell Therapy

Current advanced therapies face significant hurdles that Lentistem is actively working to overcome through innovative genetic engineering.

Lack of Efficacy

Addressing the limitations in therapeutic response for various cancer types.

Severe Toxicities

Reducing side effects to make advanced therapies safer for all patients.

Long Manufacturing

Optimizing production times to deliver life-saving treatments faster.

PROJECTS

FITHER18

Regulatable 4th generation CAR-T cells for the treatment of HER2+ solid tumors

Financed by: Actuación Conjunta ISCIII-CDTI: Innovaciones en Medicina Personalizada y Terapias Avanzadas 2022
Consortium: FIBAO, CIEMAT, LentiStem Biotec, IdisNA
Start: Jan 2023 End: Dec 2024

CARPanTu

Targeting the tumor microenvironment to improve CAR-T cell-based immunotherapy in pancreatic cancer

Consortium: University of Granada, FIBAO, FPS, LentiStem Biotech, CIMA
Reference: PLEC2021-008094/MCIN/AEI/10.13039/501100011033
Financed by: Ministerio de Ciencia e Innovación
Nov 2021 - Oct 2024
€49,574

NEOTEC

Vectores lentivirales multiregulables para inmunoterapia del génica del cáncer

Reference: EXP 00123009 / SNEO-20191072
Financed by: CDTI
Jan 2020 - Jun 2022
€203,400

Our Technological Solutions

We have developed proprietary platforms to redesign how genetic material is delivered and regulated within therapeutic cells.

Explore Pipeline

TCR-like Platform

Innovative approach for high-specificity cancer targeting.

Lent-On-Plus Platform

Controlled and inducible gene expression systems.

Our Pipeline

Our diversified pipeline of enhanced and safer CAR-T candidates, leveraging our proprietary TCR-like and Lent-On-Plus platforms.

PROGRAM | PLATFORM
INDICATION
DISCOVERY
PRE-CLINICAL
PHASE I
PHASE II

LS-CAR-01

TCR-like
Hematological Malignancies (CD19+)

LS-CAR-02

LentiOn+
Solid Tumors (HER2+)

LS-CAR-03

Lent-On-Plus
Pancreatic Cancer

LS-CAR-04

Lent-On-Plus
Glioblastoma

LentiStem Biotech is building a diversified pipeline of enhanced and safer CAR-T candidates.

KEY ACHIEVEMENTS

18+

Labs Worldwide

Using our technologies

70+

Publications

Peer-reviewed citations

10

Years

of Innovation

Investors & Strategic Value

LentiStem Biotech is seeking series-A funding to accelerate our main candidates into clinical trials. We offer a solid business model backed by high-impact IP and institutional traction.

Strong IP Portfolio

Exclusive licenses and proprietary platform technologies.

Institutional Traction

Supported by lead biotech accelerators and research centers.

Download One-Pager Request Data Room Acces (NDA)

Our Projects

Explore our ongoing funded research projects and clinical development roadmap.

View All Projects

Our Collaborators

We work with world-class hospitals and academic centers to accelerate innovation.

Meet Our Partners

News

View All News
Av. de la Ilustración, 114 (Genyo Building), 18007, Granada

Contact with us

  • Av. de la Ilustración, 114 (Genyo Building), 18007, Granada
  • info@lentistem.com

LentiStem Biotech is committed to advancing the future of immunotherapy. Reach out to learn more about our collaborations and technology.

Top